Sign Up
OverviewAPI
Improved survival and durable responses with Opdivo (nivolumab) and Yervoy (ipilimumab) in advanced renal cell carcinoma, and BAVENCIO (avelumab) reinforcing its role as a standard of care for urothelial carcinoma. These therapies demonstrate potential for enhanced survival and durable responses in patients with advanced cancers.

Ask a question